复发性高血症对心血管结果和死亡率的影响
George Bakris1, Abiy Agiro2, Fan Mu3
1AHA Comprehensive Hypertension Center, University of Chicago, Chicago, Illinois, USA.
JACC. Advances
|January 1, 2025
概括
复发性高血症 (HK) 在慢性病 (CKD) 患者,包括心力衰竭 (HF) 患者中显著增加死亡率和主要心血管不良事件 (MACE+) 的风险. 这凸显了在CKD和HF种群中管理HK的重要性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 高血症 (HK) 与严重的心血管 (CV) 结果有关,但复发性HK的具体影响尚不清楚.
- 慢性病 (CKD) 患者有增加的HK和不良心血管事件的风险.
研究的目的:
- 为了评估与慢性病患者的慢性病相关的死亡率和心血管结局,与慢性病患者的正常血量相比.
- 评估这些结局在CKD患者的子集与同时发生的心力衰竭 (HF).
主要方法:
- 使用非识别索赔数据的回顾性队列研究 (REVOLUTIONIZE III) (2016年1月 - 2022年8月).
- 包括患有3/4阶段CKD的成年人 (≥18岁),有或没有HF.
- 倾向性得分匹配分析比较患有复发性HK (≥2次事件) 患者与患有正常血的患者.
主要成果:
- 这项研究包括6337个匹配对 (2,129个HF),具有平衡的特征.
- 复发性HK与所有原因死亡率的显著更高风险相关 (HR:总体1.29,HF子研究中的1.30).
- 还观察到主要不良心血管事件加 (MACE+) (HR:整体1.53,HF子研究中的1.45) 和住院心律失常 (HR:整体1.94,HF子研究中的1.85) 的风险增加.
结论:
- 复发性高血症显著增加了CKD患者全因死亡率,MACE+和住院心律失常的风险.
- 这些增加的风险甚至在患有同时出现心力衰竭的CKD患者中仍然存在.
- 这些发现强调了在CKD和HF种群中对HK的警监测和管理的关键需要.
关键词:
行政索赔的研究研究.慢性脏疾病 慢性脏疾病心脏衰竭是因为心脏衰竭.这种高血压,高血压.主要的不良心血管事件.在正常的血清中,血清是正常的.蛋白质尿症是一种蛋白质尿症.经常性高卡利米亚的复发.氨酸- ангиотензин-алдостерон抑制剂 氨酸- ангиотензин-алдостерон抑制剂更多相关视频
03:13Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
2.1K
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
17.7K
相关概念视频
01:22Heart Failure Drugs: Diuretics
273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
636
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
636
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
395
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
395
01:28Mechanism of Cardiac Arrhythmias
847
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
847